Cutaneous lupus erythematosus: Expanding clinical trial eligibility criteria based on quality of life data.

Competing Interests: Conflicts of interest Dr Werth has grants from Pfizer, Biogen, Gilead, Corbus Pharmaceuticals, AstraZeneca, Amgen, Regeneron, CSL Behring, BMS, Horizon, Rome Pharmaceuticals, Priovant, Ventus, Viela and consults for Janssen, Lilly, Pfizer, Biogen, BMS, Gilead, Amgen, Nektar, EMD Sorona, CSL Behring, Crisalis, Viela Bio, Argenx, Kwoya Kirin, Regeneron, AstraZeneca, Abbvie, GSK, Cugene, UCB, Rome Pharmaceuticals, Horizon, Merck, Sanofi, Calyx, Cabaletta Bio, Nuvig Pharmaceuticals, Takeda, Immunovant, Anaptysbio, Evommune, Innovaderm, Alpine Immune Sciences, Caribou, Xencor, Ventus. The University of Pennsylvania owns the copyright for the CLASI. Drs Gomes, Eldaboush, Feng, and Authors Xie, Stone, and Ricco have no conflicts of interest to declare.